ZORYVE is working, but concentration still bites
- Q1 2026 net product revenue was $105.4 million, up 65% year over year despite normal first-quarter pressure.
- Management kept full-year 2026 net product revenue guidance at $480 million to $495 million.
- Operating cash flow stayed positive at $2.2 million in Q1 2026, which lowers near-term funding risk.
- The expanded dermatology sales force of about 160 reps was in the field in May 2026.
- The main worry is simple: almost all of the story still depends on the ZORYVE franchise.
Growth is real, focus is tight
Arcutis has moved from a cash-burning biotech story toward a real commercial skin-care drug company. ZORYVE demand held up in Q1 2026, with net product revenue of $105.4 million, up 65% from the year before. The company also produced $2.2 million of positive operating cash flow in the quarter.
The bull case is that ZORYVE keeps spreading across more skin diseases, more age groups, and more prescribers. The dermatology sales force has expanded to about 160 reps, and Arcutis is building its own primary care and pediatric team for a Q3 2026 launch. The June 2026 FDA approval for plaque psoriasis in children as young as age 2 adds another small but useful label expansion.
The bear case is not about whether ZORYVE is selling today. It is about how much growth investors are already paying for, and how much risk comes from relying on one franchise. Management did not raise 2026 guidance after a strong Q1, which suggests it wants to see how the new sales investments perform before getting more aggressive.
The next proof points are plain: quarterly sales versus the $480 million to $495 million 2026 guide, early prescription trends from primary care and pediatrics, progress on the infant atopic dermatitis filing, and Phase 2 vitiligo data expected in Q4 2026.
One brand, many labels
Arcutis makes money by selling ZORYVE, a roflumilast skin treatment sold as creams and foam. Different versions are approved for plaque psoriasis, seborrheic dermatitis, scalp and body psoriasis, and atopic dermatitis.
The business is now mostly funded by product revenue rather than constant new financing. That matters because many biotechs need to sell stock or raise debt before their products scale. Arcutis still has a history of net losses, but positive operating cash flow in Q1 2026 makes the financial setup less fragile.
The company sells mainly in the United States through its own dermatology sales force. For overseas markets, it uses partners, including Huadong Medicine for Greater China and Southeast Asia and Sato Pharmaceutical for Japan.
Where it can break is also clear. If doctors stop writing ZORYVE, insurers push back on coverage, a generic arrives earlier than expected, or the new primary care team fails to earn its cost, the growth story could slow fast.
What Arcutis sells and tests
ZORYVE foam 0.3%
Approved in the U.S. for seborrheic dermatitis and scalp and body psoriasis. It was the largest 2025 revenue contributor, with $181.9 million of net product revenue.
ZORYVE cream 0.3%
Approved in the U.S. and Canada for plaque psoriasis. In June 2026, the FDA expanded the U.S. label to include children as young as age 2.
ZORYVE cream 0.15%
Approved in the U.S. for mild to moderate atopic dermatitis in patients aged 6 and older. It added $68.3 million of net product revenue in 2025.
ZORYVE cream 0.05%
Approved in the U.S. for atopic dermatitis in children aged 2 and older. Arcutis submitted an sNDA in April 2026 to expand use to infants aged 3 to 24 months.
ARQ-234
A CD200R checkpoint agonist being studied for atopic dermatitis. A Phase 1a and 1b study started in March 2026.
ARQ-255
This topical JAK1 inhibitor for alopecia areata was halted in mid-2025. Its exit makes Arcutis more dependent on ZORYVE and earlier-stage work.
The 2025 revenue mix
Arcutis reports as one operating segment, so this mix uses 2025 net product revenue by ZORYVE formulation. Sales are still concentrated in the United States and in one drug franchise.
What could break the story
Primary care launch misses
High impact · Medium oddsArcutis ended the Kowa promotion deal and chose to build its own primary care and pediatric sales team. That gives it more control, but it also shifts the burden onto Arcutis. If the team fails to drive new prescriptions, the added cost could hurt operating leverage.
ZORYVE concentration
High impact · Medium oddsThe company is still built around ZORYVE. That focus helps sales execution, but it leaves little room for a product mistake, a safety concern, or a market share loss. The halt of ARQ-255 increased this concentration.
Payer pressure
High impact · Medium oddsSkin disease drugs often depend on insurance coverage and patient access programs. If insurers demand larger rebates, restrict ZORYVE use, or push cheaper alternatives first, net revenue could weaken even if prescriptions rise.
Generic and patent fights
Medium impact · Medium oddsArcutis faces a patent infringement lawsuit from Padagis tied to a proposed generic. The current stay delays the near-term threat because it extends the automatic FDA approval stay for each day the case is stayed. The final legal outcome still matters, and Teva has also filed patent oppositions in Europe.
Cash flow slips back
Medium impact · Medium oddsPositive operating cash flow is a major part of the improved thesis. Arcutis is also spending to expand its sales reach, so cash generation is not guaranteed. A return to heavy cash burn would bring financing risk back into focus.
Medicaid and tax law pressure
Medium impact · Low oddsThe company flagged that changes in U.S. tax law and Medicaid funding could hurt sales. The One Big Beautiful Bill Act may reduce Medicaid spending, which could lower covered patient access for ZORYVE.
In one breath
What does Arcutis Biotherapeutics do?
Arcutis develops and sells skin disease medicines. Its main product family is ZORYVE, which is used for conditions such as plaque psoriasis, seborrheic dermatitis, and atopic dermatitis.
How does Arcutis make money?
Most revenue comes from U.S. sales of ZORYVE creams and foam. The company also has overseas partnerships with Huadong Medicine and Sato Pharmaceutical for certain Asian markets.
Why is ZORYVE important to ARQT stock?
ZORYVE is the core of the company. If sales keep growing and new label expansions work, Arcutis can keep funding more growth. If ZORYVE slows, there is not yet another large product to offset it.
What is the next big thing to watch?
Watch whether Arcutis can hit its $480 million to $495 million 2026 revenue guide. Also watch the Q3 2026 primary care launch and the first prescription signs from that team in Q4 2026.